mounjaro tirzepatide manufacturer eli lilly cuts price of diabetes, weight-loss drugs in Canada, Globe and Mail reports FDA approves new version of

People may microdose GLP-1 medications for many reasons, including: They have hit their target weight goal They have concerns about the cost of the medications They are sensitive to the side effects of the medications They want to just suppress their appetite They are worried about the supply of the medications Microdosing GLP-1 medications can come with real risks, including: Inaccurate doses Reduced effectiveness Unpredictable outcomes Possibility of regaining weight No data on the long-term effects of microdosing Minimal oversight Large clinical trials have confirmed that the standard GLP-1 doses work well when helping people lose weight and manage Type 2 diabetes

To date, clinical trials in humans remain limited, although several are underway or in the planning phase

Phase 3 will tell us where it lands

Why Are People Switching From Tirzepatide to Retatrutide Many people begin considering switching from Tirzepatide to Retatrutide after their weight loss progress stalls or when they want improved blood sugar outcomes